Journal List > Korean J Physiol Pharmacol > v.13(6) > 1025637

Kwon, Jeong, Kwon, Son, and Kim: The Antinociceptive Effect of Sigma-1 Receptor Antagonist, BD1047, in a Capsaicin Induced Headache Model in Rats

Abstract

Intracranial headaches, including migraines, are mediated by nociceptive activation of the trigeminal nucleus caudalis (TNC), but the precise mechanisms are poorly understood. We previously demonstrated that selective blockage of spinal sigma-1 receptors (Sig-1R) produces a prominent antinociceptive effect in several types of pain models. This study evaluates whether the Sig-1R antagonist (BD1047) has an antinociceptive effect on capsaicin (a potent C-fiber activator) induced headache models in rats. Intracisternal infusion of capsaicin evoked pain behavior (face grooming), which was significantly attenuated by BD1047 pretreatment. BD1047 consistently reduced capsaicin-induced Fos-like immunore-activity (Fos-LI), a neuronal activator, in the TNC in a dose-dependent manner. Moreover, capsaicin-induced phosphorylation of N-methyl-D-aspartate receptor subunit 1 was reversed by BD1047 pretreatment in the TNC. These results indicate that the Sig-1R antagonist has an inhibitory effect on nociceptive activation of the TNC in the capsaicin-induced headache animal model.

References

Bermack J., Lavoie N., Dryver E., Debonnel G. Effects of sigma ligands on NMDA receptor function in the bulbectomy model of depression: a behavioural study in the rat. Int J Neuropsychopharmacol. 5:53–62. 2002.
crossref
Cendán CM., Pujalte JM., Portillo-Salido E., Baeyens JM. Formalin-induced pain is reduced in sigma (1) receptor knockout mice. Eur J Pharmacol. 511:73–74. 2005.
Entrena JM., Cobos EJ., Nieto FR., Cendán CM., Baeyens JM., Del Pozo E. Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. Psychopharmacology (Berl). 205:21–33. 2009.
crossref
Goadsby PJ., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 33:48–56. 1993.
crossref
Guitart X., Codony X., Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology. 174:301–319. 2004.
crossref
Kemper RH., Spoelstra MB., Meijler WJ., Ter Horst GJ. Lipo-polysaccharide-induced hyperalgesia of intracranial capsaicin sensitive afferents in conscious rats. Pain. 78:181–190. 1998.
crossref
Kim HW., Kwon YB., Roh DH., Yoon SY., Han HJ., Kim KW., Beitz AJ., Lee JH. Intrathecal treatment with sigma1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice. Br J Pharmacol. 148:490–498. 2006.
Kim HW., Roh DH., Yoon SY., Seo HS., Kwon YB., Han HJ., Kim KW., Beitz AJ., Lee JH. Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice. Br J Pharmacol. 154:1125–1134. 2008.
crossref
Kwon YB., Lee JD., Lee HJ., Han HJ., Mar WC., Kang SK., Beitz AJ., Lee JH. Bee venom injection into an acupuncture point reduces arthritis associated edema and nociceptive responses. Pain. 90:271–280. 2001.
crossref
Lipton SA. Pathologically-activated therapeutics for neuroprotection: Mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 8:621–632. 2007.
crossref
Maneepak M., Grand SL., Srikiatkhachorn A. Serotonin depletion increases nociception-evoked trigeminal NMDA receptor phosphorylation. Headache. 49:375–382. 2009.
crossref
Mitsikostas DD., Sanchez del Rio M. Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Brain Res Rev. 35:20–35. 2001.
crossref
Nuwayhid SJ., Werling LL. Sigma1 receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther. 304:364–369. 2003.
Oshinsky ML., Luo J. Neurochemistry of trigeminal activation in an animal model of migraine. Headache. 46(Suppl 1):S39–S44. 2006.
crossref
Otahara N., Ikeda T., Sakoda S., Shiba R., Nishimori T. Involvement of NMDA receptors in Zif/268 expression in the trigeminal nucleus caudalis following formalin injection into the rat whisker pad. Brain Res Bull. 62:63–70. 2003.
crossref
Park BR., Doh NY., Kim MS., Chun SW., Lee MY., Lee SH. Correlation between electrical activity of type I neuron and c-Fos expression in the medial vestibular nuclei following unilateral labyrinthectomy in rats. Korean J Physiol Pharmacol. 1:505–513. 1997.
Roh DH., Kim HW., Yoon SY., Seo HS., Kwon YB., Kim KW., Han HJ., Beitz AJ., Na HS., Lee JH. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology. 109:879–889. 2008.
Spengos K., Theleritis C., Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? Headache. 48:284–286. 2008.
crossref
Ter Horst GJ., Meijler WJ., Korf J., Kemper RH. Trigeminal nociception-induced cerebral Fos expression in the conscious rat. Cephalalgia. 21:963–975. 2001.
crossref
Yagasaki Y., Numakawa T., Kumamaru E., Hayashi T., Su TP., Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem. 281:12941–12949. 2006.
crossref
Yao D., Sessle BJ. Nitroglycerin facilitates calcitonin gene-related peptide-induced behavior. Neuroreport. 19:1307–1311. 2008.
crossref

Fig. 1.
The time spent on face grooming behavior within 10 minutes after capsaicin infusion (2.5 nmol/rat). BD1047 was introduced 10 min prior to capsaicin infusion. ∗∗p<0.01 compared to vehicle control group (first column). #p<0.05, ##p<0.01 compared to capsaicin group (second column). Each group contains 6 animals.
kjpp-13-425f1.tif
Fig. 2.
Fos-like immunoreactivity (Fos-LI) in the trigeminal nucleus caudalis (TNC) at 2 hours after intracisternal drug infusion. (A) Vehicle (artificial CSF) control, (B) capsaicin (2.5 nmol), (C) capsaicin (Cap, 2.5 nmol)+BD1047 (BD, 100 nmol). Scale bar=200 μm.
kjpp-13-425f2.tif
Fig. 3.
Number of Fos-like immunoreactive (Fos-LI) neurons in the trigeminal nucleus caudalis (TNC) at 2 hours after intracisternal capsaicin or vehicle infusion. BD1047 was introdced 10 min prior to capsaicin infusion. ∗∗p<0.01 compared to vehicle control group (first column). #p<0.05, ##p<0.01 compared to capsaicin group (second column). Each group contains 6 animals.
kjpp-13-425f3.tif
Fig. 4.
The phosphorylation of NMDA-receptor subunit 1 (pNR1) positive immunoreactivity in the trigeminal nucleus caudalis (TNC) at 2 hours after intracisternal drug infusion. (A) Vehicle (artificial CSF) control, (B) capsaicin (2.5 nmol), (C) capsaicin (Cap, 2.5 nmol)+BD1047 (BD, 100 nmol). Scale bar=200 μm.
kjpp-13-425f4.tif
Fig. 5.
The phosphorylation of NMDA-receptor subunit 1 (pNR1) immunoreactivity in the trigeminal nucleus caudalis (TNC) at 2 hours after intracisternal capsaicin or vehicle infusion. BD1047 was introduced 10 min prior to capsaicin infusion. p<0.05, ∗∗p<0.01 compared to vehicle control group (first column). #p<0.05, ##p<0.01 compared to capsaicin group (second column). Each group contains 6 animals.
kjpp-13-425f5.tif
TOOLS
Similar articles